Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01829373 · ClinicalTrials.gov registry record · Phase 1
Lung Cancer Vaccine Plus Oral Dietary Supplement
A Phase 1 study, sponsored by Edward Hirschowitz.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT01829373: Completed Phase 1 study, sponsored by Edward Hirschowitz.
NCT01829373 is a Phase 1 study that has completed, run by Edward Hirschowitz. The registered enrollment target is 5 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01829373, a Phase 1 study, has completed, sponsored by Edward Hirschowitz.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
This study tests the ability of the allogeneic cellular vaccine 1650-G vaccine to enhance immune recognition of tumor cells in patients with lung cancer. The vaccine is combined with an oral medication called beta glucan, an over the counter oral dietary supplement that may also stimulate the immune system in ways that helps the body eradicate cancer cells and reduce risk of recurrent cancer. The primary purpose of this study is to measure the changes in the number of immune cells that might help lower risk of cancer recurrence. The investigators do not yet know if the vaccine is effective in fighting cancer and will not know at the end of this study whether this has been of benefit.
Interventions
- BIOLOGICAL vaccine 1650-G
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2011-10 |
| Est. Completion | 2013-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01829373
The ClinicalTrials.gov registry entry for NCT01829373 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Edward Hirschowitz, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which vaccine 1650-G is the first listed.
NCT01829373 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01829373 about?
NCT01829373 is a clinical study titled "Lung Cancer Vaccine Plus Oral Dietary Supplement". This study tests the ability of the allogeneic cellular vaccine 1650-G vaccine to enhance immune recognition of tumor cells in patients with lung cancer. The vaccine is combined with an oral medication called beta glucan, an over the counter oral dietary supplement that may also stimulate the immune...
What is the current status of trial NCT01829373?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2011-10. Estimated completion is 2013-02.
What interventions are being tested in trial NCT01829373?
The interventions under investigation include: vaccine 1650-G (BIOLOGICAL).
Who is sponsoring clinical trial NCT01829373?
This trial is sponsored by Edward Hirschowitz, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.